Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at SEK 832.8B, ahead of Gilead Sciences (SEK 370.1B) and Biogen (SEK 113.7B). Figures as of 18 Nov 2026, 14:10 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSEK 832.8B
- Median
- SEK 7.1B
- Combined market value
- SEK 8.63T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SEK 832.8B | SEK 2.52T | SEK 4,655.02 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SEK 370.1B | SEK 2.15T | SEK 1,730.75 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | SEK 113.7B | SEK 376.8B | SEK 2,549.37 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | SEK 37.5B | SEK 850.6B | SEK 2,102.20 | 3.93% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | SEK 31.2B | SEK 213.9B | SEK 862.63 | 0.47% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | SEK 25.4B | SEK 104.4B | SEK 505.73 | 0.12% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | SEK 25.2B | SEK 111.2B | SEK 975.57 | 0.55% down | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SEK 14B | SEK 170.7B | SEK 1,686.64 | 0.37% up | 20% up | ||
| 9 | argenxARGX · Health Care | SEK 13.8B | SEK 605.7B | SEK 9,631.88 | 0.36% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | SEK 10.2B | SEK 67.7B | SEK 63.64 | 4.68% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | SEK 8.6B | SEK 105.4B | SEK 1,648.62 | 0.37% down | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | SEK 7.4B | SEK 357.7B | SEK 1,653.80 | 2.50% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | SEK 6.9B | SEK 169.9B | SEK 696.33 | 2.09% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | SEK 4.9B | SEK 116B | SEK 738.31 | 0.22% down | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SEK 3.5B | SEK 39.6B | SEK 408.14 | 0.54% down | 21% down | ||
| 16 | VaxcytePCVX · Health Care | SEK 3.2B | SEK 95.6B | SEK 603.82 | 3.59% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | SEK 2.9B | SEK 46.9B | SEK 289.61 | 2.22% up | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | SEK 2B | SEK 64.3B | SEK 984.01 | 3.90% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | SEK 1.7B | SEK 77.6B | SEK 1,138.52 | 6.63% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | SEK 1.7B | SEK 105.5B | SEK 1,235.29 | 3.44% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | SEK 1.6B | SEK 55.9B | SEK 458.25 | 1.21% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | SEK 1.2B | SEK 89.9B | SEK 3,034.87 | 0.22% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | SEK 1.1B | SEK 69.9B | SEK 337.59 | 0.21% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | SEK 396.3M | SEK 71.7B | SEK 802.45 | 6.89% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 10.1654 SEK).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (SEK 832.8B), Gilead Sciences (SEK 370.1B) and Biogen (SEK 113.7B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 14:10 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of SEK 8.63T as of 18 Nov 2026, 14:10 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.